Long-term efficacy and safety of inclisiran in patients with high ... - The Lancet
Introduction
Lowering LDL cholesterol is an established, effective, pharmacological approach to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). Current guidelines recommend risk-based LDL cholesterol goals with the aim of maintaining lower LDL cholesterol concentrations long term for those patients at greatest risk of future ASCVD-related events.
1
Vallejo-Vaz AJ
Bray S
Villa G
et al.
Implications of ACC/AHA versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI.
,
2
Ference BA
Yoo W
Alesh I
et al.
Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.
,
3
Ray KK
Molemans B
Schoonen WM
et al.
EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.
Statin monotherapy results in only 20–40% of very high-risk patients achieving new, lower, recommended LDL cholesterol goals, meaning that those not at goal will not only be required to use combination therapies, but also to be adherent to the additional medication prescribed.
1
Vallejo-Vaz AJ
Bray S
Villa G
et al.
Implications of ACC/AHA versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI.
,
3
Ray KK
Molemans B
Schoonen WM
et al.
EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.
Injectable therapies directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged, which further reduce LDL cholesterol concentrations, with two approaches currently available. The most common regimen used globally are monoclonal antibodies (mAbs) that bind circulating PCSK9. These require subcutaneous injections every 2 weeks, cumulating in approximately 26 injections per year. These have been extensively studied with long-term safety and reductions in cardiovascular events shown.
4
Sabatine MS
Giugliano RP
Keech AC
et al.
Evolocumab and clinical 0utcomes in patients with cardiovascular disease.
,
5
Schwartz GG
Steg PG
Szarek M
et al.
Alirocumab and cardiovascular outcomes after acute coronary syndrome.
Research in contextEvidence before this studyWe searched PubMed on Aug 31, 2022, without any applied restrictions using the search terms "ASCVD", "LDL-C", "atherosclerotic cardiovascular disease", "low density lipoprotein cholesterol", "PCSK9", "proprotein convertase subtilisin/kexin type 9", "inclisiran", "evolocumab", "alirocumab", "guideline", "siRNA", "long term", "efficacy", "effectiveness", and "safety". In patients at highest risk of atherosclerotic cardiovascular disease (ASCVD), lowering LDL cholesterol reduces the long-term risk of cardiovascular events, hence guidelines recommend lowering LDL cholesterol goals for those at highest risk. However, the vast majority of patients fail to achieve these recommended LDL cholesterol concentrations with statin monotherapy, and require the use of adjunct oral therapies daily (ezetimibe, bempedoic acid, or both) or injectable therapies every 2 weeks (monoclonal antibodies against PCSK9). Inclisiran is a first-in-class small interfering ribonucleic acid (siRNA) therapy which prevents hepatic PCSK9 production and can be administered every 6 months (after initial and 3-month doses) providing a convenient approach to lower LDL cholesterol. In the three phase 3 trials, inclisiran administered on days 1 and 90 and 6 monthly thereafter provided placebo-corrected LDL cholesterol reduction of up to 52% over 18 months and was well tolerated.Added value of this studyTo the best of our knowledge, ORION-3 provides the largest evidence base to date of any siRNA-based therapy showing the safety of repeat exposure to inclisiran over an additional 4 years beyond the original 1-year observation period of ORION-1. It shows that the long-pharmacodynamic effect of inclisiran through its novel mechanism of action is not only well tolerated but makes sustained additional reductions of LDL cholesterol feasible through twice-yearly dosing. There were no additional safety signals observed over approximately 5 years of exposure to inclisiran from the start of ORION-1 through to the end of ORION-3. Furthermore, there were no safety concerns when patients were switched from evolocumab twice a month to inclisiran twice a year.Implications of all the available evidenceThese data provide novel evidence that preventing production of hepatic PCSK9 consistently with the siRNA-therapeutic inclisiran is well tolerated and results in sustained reductions in circulating PCSK9 and LDL cholesterol through twice-yearly dosing for up to 5 years of total observation. For those patients who require additional LDL cholesterol-lowering despite maximally tolerated statins or those who are statin-intolerant, twice-yearly inclisiran could offer a convenient, safe, and potent option as an add-on lipid-lowering therapy. Furthermore, siRNA-based therapies against other biological pathways might offer convenient dosing schedules with a good tolerability profile to manage chronic conditions or risk factors which are amenable to this approach.
More recently, inclisiran has emerged as an alternative approach against PCSK9. It uses small interfering ribonucleic acid (siRNA)-based technology which degrades PCSK9 mRNA in the liver, inhibiting translation, and thus eliminating the main source of PCSK9 in the circulation.
6
Fitzgerald K
Frank-Kamenetsky M
Shulga-Morskaya S
et al.
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
,
7
Kosmas CE
Muñoz Estrella A
Sourlas A
et al.
A new promising agent in the management of hypercholesterolemia.
,
8
Nair JK
Willoughby JLS
Chan A
et al.
Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
,
9
Fitzgerald K
White S
Borodovsky A
et al.
A highly durable RNAi therapeutic inhibitor of PCSK9.
,
10
Ray KK
Landmesser U
Leiter LA
et al.
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
,
11
Wright RS
Ray KK
Raal FJ
et al.
Pooled patient-level analysis of Inclisiran trials is patients with familial hypercholesterolemia or atherosclerosis.
This novel mechanism allows twice-yearly dosing and has been shown to be well tolerated up to 18 months in the placebo-controlled ORION-9, ORION-10, and ORION-11 trials.
11
Wright RS
Ray KK
Raal FJ
et al.
Pooled patient-level analysis of Inclisiran trials is patients with familial hypercholesterolemia or atherosclerosis.
,
12
Raal FJ
Kallend D
Ray KK
et al.
Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia.
,
13
Ray KK
Wright RS
Kallend D
et al.
Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.
However, these trials exposed patients to only four inclisiran injections, with the twice-yearly inclisiran dosing interval used from second dose onwards only assessed over a 1-year period in those three trials.
ORION-1, was a blinded, placebo-controlled, phase 2, dose-finding and dosing schedule study of inclisiran over 1 year,
10
Ray KK
Landmesser U
Leiter LA
et al.
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
and served as a feeder study into this two-arm, 4-year, open labelled extension study (ORION-3). The primary aim of ORION-3 trial was to evaluate whether twice-yearly inclisiran provided sustained reductions in LDL cholesterol at day 210. Secondary endpoints included whether this reduction was maintained over 4 years, the percentage change of PCSK9 levels over 4 years, and whether repeat exposure to a hepatocyte-directed siRNA therapeutic had an acceptable safety and tolerability profile in patients at increased risk of cardiovascular diseases who have elevated LDL cholesterol concentrations. The exploratory endpoints included evaluating the second arm for the efficacy and safety of switching from one PCSK9 lowering approach to another, namely, patients who are switched from a twice-monthly mAb directed against PCSK9 (evolocumab) to a twice-yearly siRNA (inclisiran).
Methods
Study design and participants
ORION-3 is the open-label, multicenter, long-term (4-year) extension study of the 1-year ORION-1 study conducted across 52 study sites in five countries (figure 1, appendix pp 1–2). ORION-1 was a phase 2, multicenter, 1-year, double-blind, placebo-controlled, dose-finding study of inclisiran administered as a subcutaneous injection in patients at high risk of ASCVD with elevated LDL cholesterol concentrations. Inclisiran sodium was administered as a single dose of 200 mg, 300 mg, or 500 mg on day 1 or two doses of 100 mg, 200 mg, or 300 mg on day 1 and day 90. The study design and results of ORION-1 have been published in detail previously.
10
Ray KK
Landmesser U
Leiter LA
et al.
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
Figure 1Study design
Show full caption
*Day 810 injection in the inclisiran-only arm was administered as a one-time 90-day dosing interval as per the initial study design for exploratory purposes. In the switching arm patients received the second inclisiran dose 90 days apart on day 450.
ORION-3 was conducted in accordance with the trial protocol, principles of the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice, and was approved by the Institutional Review Boards of each facility. Written informed consent was required and obtained from each patient for this open-label extension trial before trial enrolment (separate from the informed consent required for the ORION-1 phase 2 trial).
Patients aged 18 years and older with prevalent ASCVD or high-risk primary prevention (defined as either type 2 diabetes, familial hypercholesterolemia, or a 10-year risk of a cardiovascular event >20%) and elevated LDL cholesterol (≥1·8 mmol/L [≥70 mg/dL] for ASCVD patients or ≥2·6 mmol/L [≥100 mg/dL] for high-risk primary prevention in ORION-1) despite maximally tolerated statins or other LDL-lowering treatments, or with documented statin intolerance, who had completed the predefined 1-year of observation in the ORION-1 trial were invited to enroll in ORION-3.
Detailed inclusion and exclusion criteria are provided in the appendix (pp 3–4). Briefly, patients were excluded if they had any uncontrolled or serious medical or surgical condition that reduced life expectancy, or previous or current treatment with a mAb directed against PCSK9. Pregnant or lactating women were also excluded from the trial. Finally, patients randomly assigned in the original ORION-1 trial had to consent to an extended participation in the ORION-3 trial.
Randomisation and masking
The ORION-1 trial has been published,
10
Ray KK
Landmesser U
Leiter LA
et al.
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
and the randomisation into treatment arms has been explained and discussed in this publication. ORION-3 was an open-label study and included two treatment arms: inclisiran-only arm and switching arm.
Procedures
Patients who received inclisiran sodium (100 mg, 200 mg, or 300 mg in two doses or 200 mg, 300 mg, or 500 mg as a single dose) in ORION-1 received 300 mg subcutaneous inclisiran sodium (equivalent to 284 mg inclisiran; twice-yearly subcutaneous dosing) throughout ORION-3 (inclisiran-only arm). Patients in the inclisiran-only arm received inclisiran on days 1, 180, 360, 540, 720, 810, 990, 1170, and 1350.
Patients who received placebo in ORION-1 received open-labeled 140 mg subcutaneous evolocumab (dosed every 2 weeks) for up to 1 year and then transitioned to 300 mg subcutaneous inclisiran sodium (equivalent to 284 mg inclisiran) for the remainder of the study (switching arm). In this arm, patients were randomly allocated to either staged switch (day 336, final dose of evolocumab therapy; day 360, first dose of inclisiran) or concurrent switch (day 360, final dose of evolocumab and the first dose of inclisiran at clinic visit). After the first inclisiran dose (day 360), subsequent doses were administered 90 days later (ie, day 450) and 6-monthly thereafter on days 630, 810, 990, 1170, and 1350. All patients received the assigned treatments over an open-label follow-up period of 4 years (figure 1).
Inclisiran was administered as a single subcutaneous injection of 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) through a 1·5 mL solution packaged in a glass vial by a health care professional at the study site. Evolocumab was self-administered by the patient as a single 1·0 ml subcutaneous injection using a single-use auto-injector containing 140 mg of evolocumab.
Fasting blood samples were obtained at each study visit, and LDL cholesterol concentrations were measured by combining ultracentrifugation with precipitation. PCSK9 analysis was performed using Quantikine ELISA from R&D Systems according to the manufacturer's instructions using a Tecan Sunrise reader and EDTA-plasma. A full description of the methods used to measure prespecified laboratory parameters is available in the appendix (p 5); the methods were the same as in the ORION-1 trial.
10
Ray KK
Landmesser U
Leiter LA
et al.
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
Outcomes
The primary endpoint of the ORION-3 trial was the percentage change in LDL cholesterol from baseline of ORION-1 to day 210 in this study for the inclisiran-only arm—ie, an observation period of approximately 570 days from first inclisiran injection. Secondary endpoints included percentage and absolute change from baseline of ORION-1 in LDL cholesterol and PCSK9 over time; percentage and absolute change from baseline of ORION-1 in other lipids and lipoproteins over time; individual response to inclisiran defined as the number of patients achieving prespecified LDL cholesterol thresholds of less than 0·6 mmol/L (<25 mg/dL), less than 1·3 mmol/L (<50 mg/dL), less than 1·8 mmol/L (<70 mg/dL), and less than 2·6 mmol/L (<100 mg/dL) at any time point for the inclisiran-only arm and long-term safety and tolerability (adverse events, laboratory abnormalities and serious adverse events, with their severity and relationship to study treatment) of inclisiran.
In the switching arm, patients were on placebo during ORION-1, thus the ORION-3 baseline data (defined as the last available measurement before the first evolocumab administration in ORION-3) was used to assess change in LDL cholesterol, PCSK9, and other efficacy parameters, instead of the baseline data of ORION-1 (unlike the inclisiran-only arm who received inclisiran in ORION-1). Correspondingly, the exploratory endpoints for the switching arm were the percentage and absolute change from ORION-3 baseline in LDL cholesterol, PCSK9, and other efficacy parameters. An additional exploratory endpoint was the safety of transitioning from evolocumab (mAb) to inclisiran on the day 360 visit.
LDL cholesterol percentage change averaged for each year of the open-labeled extension phase was also evaluated (post-hoc analysis).
Statistical analysis
There was no formal sample size calculation for this study. Data collected were summarised by treatment arm (inclisiran-only arm and switching arm) using descriptive statistics, graphs, or raw data counts, or combination of these metrics, as appropriate. Categorical variables were summarised using numbers and percentages. Percentages were based on the number of patients in the analysis set for whom there was non-missing data, unless otherwise specified. Continuous variables, including changes from baseline of ORION-1 or ORION-3 (inclisiran-only and switching arm respectively), were summarised using descriptive statistics. For the primary endpoint, mean and 95% CI for the percentage change and p value are reported (inclisiran-only arm); for secondary and exploratory efficacy endpoints, 95% CIs for the mean, median, or proportion are provided. The p value for the primary endpoint was based on the t-test for the null hypothesis of mean=0. CIs for the mean were constructed by inverting the t-test statistic, CIs for the median were constructed using the distribution-free method based on binomial probabilities, and CIs for the proportion used Blaker's method. Safety analyses are descriptive and reported as counts and proportions.
As a post-hoc analysis, the mean percentage change from ORION-1 baseline in LDL cholesterol concentration averaged over time for modified ITT (mITT; all patients who received at least one dose of study drug and for whom both baseline and the day 210 follow-up LDL cholesterol concentration measurements were available) population in the inclisiran-only arm were analysed for the entire 4-year duration of ORION-3 and for each of the 4 years. The average over time was calculated as the arithmetic mean of the least squares means at each study visit, estimated using a mixed-effects model for repeated measurements which included study visits as the fixed effect. For the switching arm ITT population, the same was analysed from ORION-3 baseline for year 1, the 3-year period from year 2 to year 4, and each of the last 3 years.
Analyses for the inclisiran-only arm were performed in the ITT and the mITT population; mITT was the primary population used for presentation whenever available. All patients who received at least one dose of inclisiran were included in the safety analysis (safety population). All analyses were performed with SAS software (version 9.4). ORION-3 is registered with ClinicalTrials.gov, NCT0360577.
Role of the funding source
The ORION-3 trial was initiated by The Medicines Company, which was subsequently purchased by Novartis. Novartis continued the ORION-3 trial through to completion. Data analyses were performed by Novartis and a designated external service provider in accordance with the statistical analysis plan prepared by a qualified statistician.
Results
The first patient visit for ORION-3 occurred on March 24, 2017, recruitment continued until Nov 22, 2017, and the last patient visit was on Dec 17, 2021. In the blinded, placebo-controlled ORION-1 trial, 370 patients received inclisiran and 127 received placebo. Of those patients in the inclisiran arms, 290 of 370 agreed to continue into the twice-yearly inclisiran-only open-labelled extension arm for 4 years. In the placebo arms, 92 of 127 agreed to continue the trial and to first have evolocumab twice-monthly for 1 year and then twice-yearly inclisiran for 3 years (switching-arm). Of these, 233 (80%) in the inclisiran-only arm and 80 (87%) in the switching arm completed the full 4-year study observation period. The ITT population comprised 382 patients (inclisiran-only and switching arm) and of these, the mITT population comprised 277 patients in the inclisiran-only arm and 88 patients in the switching arm. The primary reason for discontinuation irrespective of treatment arm was the withdrawal of consent (25 of total 57 discontinuations in the inclisiran-only arm and five of total 12 discontinuations in the switching arm; appendix p 6).
Patient demographic and clinical characteristics are summarised in table 1. Overall, the mean age of patients in the study was 63·0 years (SD 11·0), 64% (n=243) were men, 94% (n=356) were White, 4% (n=15) Black or African American, 1% (n=4) American Indian or Alaska Native, and 1% (n=4) Asian. The mean baseline LDL cholesterol was 3·33 (SD 1·30) mmol/L for the inclisiran-only arm and 3·17 (1·35) mmol/L for the switching arm (table 1). In the inclisiran-only arm, during the open-label extension phase, there were 1045·5 patient-years of exposure to inclisiran resulting in a total cumulative exposure to inclisiran starting from the beginning of ORION-1 through to the end of ORION-3 of 1209·6 patient-years. In the switching arm, the exposure to inclisiran was 250·2 patient-years.
Table 1Baseline demographic and clinical characteristics for the ORION-3 study participants
Data are mean (SD), n/N (%), or mean (SD), n. ASCVD=atherosclerotic cardiovascular disease. BMI=body-mass index. eGFR=estimated glomerular filtration rate. ITT=intention-to-treat. LDL=low-density lipoprotein. mITT=modified intention-to-treat. PCSK9=proprotein convertase subtilisin/kexin type 9.
In the inclisiran-only arm, LDL cholesterol concentrations at day 210 were −1·56 (95% CI −1·68 to −1·44) mmol/L reflecting a reduction of 47·5% (95% CI −50·7 to −44·3; pfigure 2A and the percentage and absolute changes are shown in table 2. During the 4 years of the open-labeled extension, the mean percentage change and mean absolute change in LDL cholesterol concentrations ranged between −34·3% to −53·8%, and −1·13 mmol/L to −1·76 mmol/L, respectively with upper bounds of 95% CIs at all time points being lower than −30% and excluded zero (figure 2 and table 2). Two injections of inclisiran per year provided annual average reductions in LDL cholesterol of 42·5%, 44·5%, 49·4%, and 45·4% in each year of the open-label extension, and an overall 4-year time-averaged reduction of 44·2% through 9 injections (table 3).
Figure 2Mean percentage change in LDL cholesterol (A) from ORION-1 baseline to day 1440 (4 years) of ORION-3 (inclisiran-only arm), and from (B) ORION-3 baseline to day 1440 (4 years) of ORION-3 (switching arm)
Show full caption
LDL=low-density lipoprotein. *D810 injection was administered as a one-time 90-day dosing interval as per the initial study design for exploratory purposes. (A) The vertical rectangle denotes the primary endpoint at day 210; baseline is representative of ORION-1 baseline; analysis was carried out in the modified intention-to-treat population. (B) Baseline is representative of ORION-3 baseline; the analysis was carried out in the intention-to-treat population.
Table 2Percentage and absolute change in LDL cholesterol from baseline
*
For the inclisiran-only arm, data were analysed in the mITT population; for the switching arm, data were analysed in the ITT population. The inclisiran-only arm uses ORION-1 baseline and the switching arm uses ORION-3 baseline.
by treatment arm and visit day
Data are n or mean (95% CI). ITT=intention-to-treat. mITT= modified intention-to-treat. NA=not applicable.
Table 3Mean percentage change from baseline in LDL cholesterol averaged over time by treatment group
Data are n or least squares mean (95% CI). ITT=intention-to-treat. LDL=low-density lipoprotein. mITT=modified intention-to-treat.
The mean percentage change in PCSK9 concentrations ranged between −62·2% to −77·8% over 4 years in the inclisiran-only arm (appendix pp 7−8). Following the first dose of inclisiran during the open-label extension, the mean percentage change (95% CI) in PCSK9 concentrations 30 days later was −71·8% (−73·2 to −70·4), and was −69·5% (−71·2 to −67·9) at 1440 days with twice-yearly dosing. The percentage and absolute change in PCSK9 concentrations are shown in the appendix (p 8).
The mean percentage change in non-HDL cholesterol and apoB concentrations ranged between −41·7% and −30·0%, and −40·4% and −26·5%, respectively, throughout the study period, with mean absolute change for the same parameters ranging from −1·72 mmol/L to −1·23 mmol/L, and −42·6 mg/dL to −27·9 mg/dL, respectively (appendix, pp 8−10) with changes observed early and maintained throughout the study. Percentage and absolute change in lipoprotein(a) [Lp(a)], triglycerides, very low-density lipoprotein cholesterol (VLDL cholesterol) calculated, VLDL cholesterol directly measured, and high-sensitivity C-reactive protein (hsCRP) over the study period are shown in the appendix (pp 8−10). Most patients (93%) in the inclisiran-only arm achieved an LDL cholesterol level of less than 2·6 mmol/L at any time point during the study, and 79% of patients achieved LDL cholesterol concentrations of less than 1·8 mmol/L and 62% that of less than 1·3 mmol/L (appendix p 10).
In the switching arm, treatment with evolocumab resulted in percentage LDL cholesterol reductions ranging between 47·8% and 65·7% (figure 2B and table 2) and a time-averaged reduction during that year of 61·0% (95% CI 64·5−57·4) through 25 injections (table 3). After switching to inclisiran, the time-averaged reduction in LDL cholesterol in each subsequent year was 47·9% (−51·8 to −44·0), 45·4% (−50·8 to −40·1), and 43·9% (−49·5 to −38·3), respectively, reflecting a time-averaged 3-year LDL cholesterol reduction of 45·3% (−49·7 to −40·9) through 7 injections (figure 2B, table 2 and table 3).
Irrespective of the timing of the switch from evolocumab to inclisiran (staged or concurrent), LDL cholesterol concentrations and PCSK9 reductions on inclisiran were generally similar over years 2–4 (appendix pp 10−12) and similar to the inclisiran-only arm (table 3). Similarly, during years 2–4, changes in other lipids and lipoproteins in the switching arm resembled changes observed with the inclisiran-only arm (appendix pp 12−14). The proportion of patients achieving >50% lowering of LDL cholesterol varied in the switching arm and was higher during evolocumab treatment (appendix pp 14−15).
Over the follow-up period, treatment-emergent adverse events were reported in 275 (97%) of 284 patients in the inclisiran-only arm and 80 (92%) of 87 patients in the switching arm. Although spanning a large array of system categories in a patient population with many comorbidities at baseline, these treatment-emergent adverse events were for the majority, single cases, mild-to-moderate in severity, and self-limited. The most common treatment-emergent adverse event was nasopharyngitis (55 [19%] of 284) in the inclisiran-only arm and hypertension (17 [20%] of 87) in the switching arm (appendix pp 15). Treatment-emergent adverse events possibly related to study medication (as determined by the investigator) occurred in 79 (28%) of 284 patients in the inclisiran-only arm and 22 (25%) of 87 patients in the switching arm; most were general disorders and administration site reactions that included injection site pain, injection site reaction, injection site erythema etc (appendix pp 16–17). Three patients (3%) in the switching arm had increases in hepatic enzymes that were felt to be related to the study medication. No new safety signals were detected in either of the transition arms upon switching from evolocumab to inclisiran (appendix p 16). The proportion of patients with at least one treatment-emergent adverse event at the injection site was 14% (39 of 284) in the inclisiran-only arm over the entire 4-year duration of the trial. In the switching-arm, the proportion of patients with at least one treatment-emergent adverse event at the injection site was 8% (seven of 90; appendix p 17) during the first year on evolocumab and 14% (12 of 87) for the 3 years following the transition to inclisiran (appendix p 18).
The incidence of treatment-emergent serious adverse events was 37% (104 of 284) in the inclisiran-only arm and 34% (30 of 87) in the switching arm. A total of eight deaths (2%) were reported during the study, seven deaths (2%) in the inclisiran-only arm and one death (1%) in the evolocumab switched to inclisiran arm: none were considered to be related to the study medication but included a variety of conditions such as COVID-19 infection, respiratory failure, ischemic stroke, coronary artery event as well as aortic aneurysm rupture (appendix p 18). Treatment-emergent serious adverse events possibly related to study drug (as reported by the investigator) occurred in three patients (1%) in the inclisiran-only arm and in one patient (1%) in the switching arm (appendix pp 18–19). These four adverse events included one patient with an accessory pathway-mediated tachycardia considered to be exacerbated by study medication, one acute cholecystitis in a patient known with gallstones, one case of hepatic fibrosis in a patient with fatty liver disease at baseline, and one case of peak increases in alanine aminotransferase (ALT) and aspartate transaminase (AST) greater than than 5 × upper limit of normal in a patient with chronic hepatitis C as well as high alcohol intake. Treatment-emergent hepatic events were carefully examined during the study: 28 (10%) of 284 patients in the inclisiran-only arm and eight (9%) of 87 patients in the switching arm experienced at least one treatment-emergent hepatic event. Aside from the two hepatic treatment-emergent serious adverse events described above, most treatment-emergent hepatic events were increases in liver enzymes reported as mild or moderate in severity. The summary of clinically significant liver chemistry abnormalities is also presented in table 4, and no single case reported in this study met the criteria for Hy's Law.
14
Hy's law: predicting serious hepatotoxicity.
Table 4Summary of adverse events and clinically relevant laboratory measurements by treatment arm
Data are n (%). UMC=Uppsala Monitoring Centre.
Discussion
ORION-3 provides the first prospective long-term evaluation of the durability and safety of an siRNA-based therapy to provide clinically meaningful reductions in LDL cholesterol with a convenient dosing schedule. At the primary endpoint day 210 of this study, inclisiran administered by a health-care professional twice-yearly provided sustained reductions in circulating PCSK9 concentrations of 76·4%, which, in turn, resulted in reductions in LDL cholesterol concentrations of 47·5%. In addition, the ORION-3 trial confirmed the durability of reductions in other atherogenic lipids and lipoproteins such as non-HDL cholesterol and apoB over 4 years, compared to the reductions observed over 6 months and 18 months in previous trials.
10
Ray KK
Landmesser U
Leiter LA
et al.
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
,
11
Wright RS
Ray KK
Raal FJ
et al.
Pooled patient-level analysis of Inclisiran trials is patients with familial hypercholesterolemia or atherosclerosis.
,
15
Ray KK
Stoekenbroek RM
Kallend D
et al.
Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1.
Thus, this open-label extension study shows that twice-yearly dosing of an siRNA targeting hepatic PCSK9 synthesis is a feasible therapeutic option by which sustained LDL cholesterol-lowering can be achieved. With 4 years of extended exposure, the most common adverse events in the inclisaran only arm observed were nasopharyngitis reported in 19% of patients and adverse events at the injection site in 14% of patients. In phase 3 trials of 3600 patients, nasopharyngitis and adverse events at the injection site were reported in 7·6% and 5·0% of inclisiran-treated patients, respectively, over 18 months with adverse events at the injection site also common during 8 months of treatment in phase 2 trials (3·8–6·5%).
High blood pressure is a common condition that puts extra stress on blood vessels and vital organs. Diagnosing the condition - which is also known as hypertension - early is crucial, as it raises the risk of some deadly complications, including heart disease and strokes. But making some small diet or lifestyle changes could help to lower your chances of developing high blood pressure . You should definitely get a blood pressure check as soon as you turn 60 years old, urged LloydsPharmacy. Hypertension is most common in people over 60 years old, said LloydsPharmacy. As soon as you’ve hit 60, it’s a good idea to speak to a doctor our pharmacist to check your blood pressure. Even if you only have slightly high blood pressure, diagnosing the condition early can help patients to kickstart their new lifestyle changes, it said. “It’s only natural that people might not think to seek help from a health professional until something starts to feel wrong, especially as we are all livin...
clinical trials day :: Article Creator Everyday Drug Discovery: How Tech Expands The Potential Of Clinical Trials And Recentres Participants Throughout my career in the development and implementation of technological solutions to support clinical research, I've been lucky enough to work closely with a wide range of so-called "stakeholders" in the clinical trial lifecycle, from regulators, drug development research teams, site staff, and patients. While all groups have demonstrated an inspiring level of dedication and passion, I have always been moved by patients' willingness to sacrifice their time and adapt their care plans to take part in clinical trials, fully understanding they might not directly benefit from the treatment being tested, though so often desperately hoping they do. Patients recognise the importance of clinical research to the long term success in treating diseases of all kinds, and in turn the industry has t...
Some people claim to have a sixth sense that lets them know when something is about to happen. Although most people aren't clairvoyant, there is some truth to having a gut feeling about future events. People have claimed to turn down job offers, decline evening plans and forgo vacations just because they had a feeling that things were about to take a turn for the worse. And when these feelings prove to be right, it's evident that maybe there is a reason that people have these instincts. The gut wrenching feeling that you have to act now just can't be ignored. Having a life-threatening experience is memorable enough, but narrowly avoiding one by seconds is just as unforgettable. He's Still in Jail Unsplash My oldest daughter (30-something) stopped by my work one day and introduced her new boyfriend. He seemed a little off to me, but I decided it was just "guy dating my daughter" and let it go. La...
